Outcome assessment by central adjudicators in randomised stroke trials: Simulation of differential and non-differential misclassification

Author:

Godolphin Peter J12ORCID,Bath Philip M34,Partlett Christopher1,Berge Eivind5,Brown Martin M6,Eliasziw Misha7,Sandset Per Morten8ORCID,Serena Joaquín9,Montgomery Alan A1

Affiliation:

1. Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK

2. MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, London, UK

3. Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK

4. Stroke, Nottingham University Hospitals NHS Trust, Nottingham, UK

5. Department of Internal Medicine, Oslo University Hospital, Oslo, Norway

6. Stroke Research Group, UCL Institute of Neurology, University College London, London, UK

7. Department of Public Health and Community Medicine, Tufts University, Boston, MA, USA

8. Department of Haematology, Oslo University Hospital and University of Oslo, Oslo, Norway

9. Stroke Unit, Department of Neurology, IDIBGI, Hospital Josep Trueta, Girona, Spain

Abstract

Introduction Adjudication of the primary outcome in randomised trials is thought to control misclassification. We investigated the amount of misclassification needed before adjudication changed the primary trial results. Patients (or materials) and methods: We included data from five randomised stroke trials. Differential misclassification was introduced for each primary outcome until the estimated treatment effect was altered. This was simulated 1000 times. We calculated the between-simulation mean proportion of participants that needed to be differentially misclassified to alter the treatment effect. In addition, we simulated hypothetical trials with a binary outcome and varying sample size (1000–10,000), overall event rate (10%–50%) and treatment effect (0.67–0.90). We introduced non-differential misclassification until the treatment effect was non-significant at 5% level. Results For the five trials, the range of unweighted kappa values were reduced from 0.89–0.97 to 0.65–0.85 before the treatment effect was altered. This corresponded to 2.1%–6% of participants misclassified differentially for trials with a binary outcome. For the hypothetical trials, those with a larger sample size, stronger treatment effect and overall event rate closer to 50% needed a higher proportion of events non-differentially misclassified before the treatment effect became non-significant. Discussion: We found that only a small amount of differential misclassification was required before adjudication altered the primary trial results, whereas a considerable proportion of participants needed to be misclassified non-differentially before adjudication changed trial conclusions. Given that differential misclassification should not occur in trials with sufficient blinding, these results suggest that central adjudication is of most use in studies with unblinded outcome assessment. Conclusion: For trials without adequate blinding, central adjudication is vital to control for differential misclassification. However, for large blinded trials, adjudication is of less importance and may not be necessary.

Funder

Medical Research Council

Research Trainees Coordinating Centre

Publisher

SAGE Publications

Subject

Cardiology and Cardiovascular Medicine,Clinical Neurology

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3